Skip to content
Company Analysis

iRadimed Corporation IRMD

A comprehensive view of key metrics, scores, and financial health for iRadimed Corporation

Overview of IRADIMED CORPORATION

IRMD NGM
Healthcare Medical Devices Framework: Medical Devices & Diagnostics Small Cap
IRADIMED CORPORATION (IRMD), is a Small Cap company, in the Medical Devices industry, last closed at $79.42, about 84.4% overvalued vs fair value, -6.1% 1Y return, placing in the top 10% of its sector.
Metrics P/E 55.6× Rev Growth 14.4% ROE 24.8% Gross Margin 76.8% Div Yield 1.22%
USD 79.42
3.57%
(Delayed)
• Vol 90d: 32.6%
52-Week Range
Market Cap
$1.02B
Enterprise Value
$964.48M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Excellent
Health
Good
Efficiency
Fair
Valuation
Excellent
Growth
Fair
Profitability
Excellent
Health
Good
Efficiency
Fair
Valuation
Excellent
Completeness: 94%
Confidence: 94%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.iradimed.com
HQ Orlando, FL
Fiscal year Dec 31

Next Events

Earnings Oct 30 Call: Oct 30

Fair Value Snapshot

Bear Base Bull
$11
$12
$14
Current: $79.42 -84% vs base

Engine Room Money Flow™

Small Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$83.8M
14.4%%
Gross Profit
$64.3M
14.2%%
Operating Income (GAAP)
$26.1M
19%%
EBITDA
$27.3M
19.9%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
76.7%
Excellent

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health some concerns
Moderate efficiency issues detected. Review active leaks below for improvement areas.
2
Active Leaks
2/2
Improving
0
High Impact
0
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating iRadimed Corporation's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
83
/100
Strong
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Elite Gross Margins Gross margin quality is top-tier vs peers (score 0.80). This signals strong consumable attach-rate economics.
  • Superior Capital Returns Capital return quality is top-tier (score 0.91). High ROIC indicates the business is reinvesting at attractive rates.

Key risks

  • Operating Margin Compression Operating margin trend is negative (score 0.36). Sustained compression would reduce the commercial moat.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Strong
87
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing IRMD's balance between Growth (27.0%), Profitability (38.0%), and Safety (35.0%). Growth 27% Safety 35% Profitability 38%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

65th percentile vs peers
66
Key Signals
Rev Growth YoY 14.4% 66p Revenue CAGR 3Y 16.3% 68p EPS CAGR 3Y 19.9% 69p TSR 79.0% 92p EPS Growth YoY 16.2% 44p
Strengths
  • Gross Profit Margin in top 20% of peers (76.8%, 86th percentile)
  • FCF Margin in top 20% of peers (19.7%, 92th percentile)
  • Operating Margin in top 20% of peers (31.2%, 98th percentile)
Risks

No significant risks identified for this axis.

Profitability

92th percentile vs peers
93
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

85th percentile vs peers
85
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for iRadimed Corporation.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$12.42
- - -
-84.4% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000